Skip to main content

Table 2 Influence of treatment with GAT107 on the clinical parameters of EAE

From: Suppression of neuroinflammation by an allosteric agonist and positive allosteric modulator of the α7 nicotinic acetylcholine receptor GAT107

 

Mean severity

Cumulative score

Max score

Day of onset

Placebo

1.8 ± 0.15

33.8 ± 2.9

2.25 ± 0.14

11.2 ± 0.5

GAT107

0.4 ± 0.12**

8.1 ± 2.4**

0.68 ± 0.18**

14.2 ± 0.6*

  1. *p < 0.05, **p < 0.001
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094